Synapse - Early Drug Development Service

Search Within

Early Drug Development Service

Results (464)

Precision oncology: 2022 in review

Review

Rosen, E.; Drilon, A.; Chakravarty, D.
Cancer Discovery (2022)

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers

Meeting Abstract

Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)

Meeting Abstract

Rosen, E.; Silverman, I. M.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma

Meeting Abstract

Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors

Meeting Abstract

Meric-Bernstam, F.; Sharma, M.; Sommerhalder, D.; Skeel, R. T.; El-Khoueiry, A. B.; Caswell-Jin, J. L.; Patel, P. H.; Rosen, E.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development

Meeting Abstract

Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer

Meeting Abstract

Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Mechanisms of acquired resistance to TRK inhibitors

Meeting Abstract

Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)

Meeting Abstract

Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation

Meeting Abstract

Dumbrava, E. E.; Johnson, M. L.; Tolcher, A. W.; Shapiro, G.; Thompson, J. A.; El-Khoueiry, A. B.; Vandross, A. L.; Kummar, S.; Parikh, A. R.; Munster, P. N.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save